comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor (GLP-1 RAs) (#semaglutide #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults Cardiovascular and mortality outcomes with

Variations in genes encoding the GIP receptor (GIPR rs1800437), and fat-mass genes like FTO and MC4R determine whether your metabolism is naturally responsive to these hormones

Retrieved from American Diabetes Association Professional Practice Committee

Asthma and COPD: Although selective, beta-blockers can affect beta-2 receptors at higher doses, potentially exacerbating bronchospasms in susceptible individuals

When a persistent hypoglycemia situation cannot be treated with a single medication in conjunction with diet and exercise, a combination of metformin or insulin with glimepiride must be prescribed.[] ARBs are the recommended antihypertensive agents in diabetic hypertensive patients

Annu Rev Neurosci 27 : 581609